America Great Health, formerly known as Crown Marketing, reported its financial results for the fiscal year ending June 30, 2025, revealing a revenue increase to $391,743, up from $294,670 in the previous year. The company attributed this growth primarily to the launch of new products. The cost of goods sold decreased significantly to $52,622 from $124,920, leading to a gross profit of $339,121 compared to $169,750 in the prior year. Despite the improved revenue and gross profit, America Great Health reported a net loss of $721,242, a reduction from the $1,226,362 loss recorded in the previous fiscal year.
The company has undergone several strategic developments, including the establishment of joint ventures and acquisitions aimed at expanding its footprint in the healthcare sector. Notably, America Great Health formed a joint venture in China focused on stem cell-related products and invested in Purecell Group, an anti-aging medical institution in Australia. The company also established several subsidiaries, including Nutrature Health LLC and GOF Biotechnologies Inc., to enhance its operational capabilities in health technology and product development.
Operationally, America Great Health reported a total of five full-time employees as of June 30, 2025, with additional personnel engaged as independent contractors. The company’s cash balance at the end of the fiscal year was $44,056, down from $54,943 the previous year. The company continues to face challenges, including a working capital deficit of $3,584,235 and an accumulated deficit of $10,781,345, raising concerns about its ability to continue as a going concern. The company has relied on loans and advances from its majority shareholder to meet its cash needs.
Looking ahead, America Great Health plans to pursue additional acquisitions in the healthcare sector, particularly in the Asia Pacific region, where it sees potential for growth due to rising demand for healthcare products and services. The company is also focused on developing innovative technologies in protein and peptide drug research, diagnostic devices, and regenerative medicine. However, the management cautioned that achieving profitable operations and securing necessary capital will be critical to its future success. The company’s financial statements reflect ongoing uncertainties, and it has received a report from its auditors expressing doubt about its ability to continue as a going concern.
About America Great Health
America Great Health operates in the healthcare industry, focusing on research and development of protein and peptide small molecule drugs, diagnostic and medical devices with AI cloud computing, cell therapy, regenerative medicine, and manufacturing and sales of supplements. The company serves markets in the Asia Pacific and beyond through subsidiaries and joint ventures, leveraging innovative technologies and strategic investments to advance healthcare solutions.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.